Key data will be presented on the Company’s alpha-synuclein-positron emission tomography (PET) tracer program along with a second oral presentation by the Coordinating Principal Investigator of the Phase 1b trial of the anti-Abeta vaccine ACI-24 in Down syndrome, Dr. Michael Rafii – who is a world authority on Down syndrome-related Alzheimer’s disease. Both research programs are the most advanced in their field.
Prof.
“Compelling results1 just published from the first large, multi-national study to track clinical and biomarker changes of Down syndrome-related Alzheimer’s disease further validate the approach of testing our anti-Abeta vaccine ACI-24 in individuals with Down syndrome as a key population for trials to target Alzheimer’s disease in genetic, more homogeneous populations.
“The presentations further highlight the enduring power of our clinically validated proprietary Morphomer™ and SupraAntigen™ platforms to accelerate the discovery, design and development of novel medicines and diagnostics to target misfolded proteins.”
Scientific updates at the AAIC 2020 Virtual Event, July 27–31, 2020
Alpha-synuclein PET tracer | ||
Title: | Developing a novel alpha-synuclein-positron emission tomography (PET) tracer for the diagnosis of a-synucleinopathies | |
Date: | ||
Session: | Neuroimaging: Other Neurodegenerative Disorders | |
Presenter: | Oral presentation by Dr. |
ACI-24 anti-Abeta vaccine | ||
Title: | ACI-24 Vaccine in Adults with Down Syndrome (3 Star Trial) | |
Date: | ||
Session: | Human: Putative Therapeutic Results for Alzheimer's and Related Dementias | |
Presenter: | Oral presentation by Dr. |
References
- Fortea et al,
Lancet 2020; 395: 1988–97
About
For further information, please contact:
Head of Investor Relations Phone: +1 917 809 0814 Email: joshua.drumm@acimmune.com |
US Media LaVoieHealthScience Phone: +1 617 792 3937 Email: kgallagher@lavoiehealthscience.com |
Global Head of Communications Phone: +41 79 826 63 82 Email: judith.moore@acimmune.com |
Phone: +41 79 367 6254 Email: chris@lifesciadvisors.com |
Forward looking statements
This press release contains statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immune’s strategies or expectations. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” “outlook” or “continue,” and other comparable terminology. Forward-looking statements are based on management’s current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described under the captions “Item 3. Key Information – Risk Factors” and “Item 5. Operating and Financial Review and Prospects” in AC Immune’s Annual Report on Form 20-F and other filings with the
Source: AC Immune SA